2020–2021 Drug Updates: Investigational Therapeutics in the Pipeline
Donald C. Moore, PharmD, BCPS, BCOP, DPLA
From Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
Presenter’s disclosure of conflicts of interest is found at the end of this article.
J Adv Pract Oncol 2022;13(3):286–291 |
© 2022 Harborside™
During JADPRO Live Virtual 2021, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechanism of action, a rethinking of how to approach treating a disease, or those that have recently received FDA Breakthrough Designation status that advanced practitioners should be aware of.
For access to the full length article, please sign in